N4 Pharma PLC Operations Update (5305J)
24 August 2021 - 4:00PM
UK Regulatory
TIDMN4P
RNS Number : 5305J
N4 Pharma PLC
24 August 2021
24 August 2021
N4 Pharma plc
("N4 Pharma" or the "Company")
Operations Update
N4 Pharma plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to provide an update on its current work
streams.
Collaborations
As announced on 20 May 2021, the Company has been working on two
Material Transfer Agreements ("MTAs") to assess how well Nuvec(R)
can bind and be optimised for transfection with two different
proprietary nucleic acid products. The first agreement is with a
major international company working in the gene therapy space and
the second is with a UK based pharmaceutical company developing its
its own proprietary vaccine for Covid-19 using a DNA plasmid.
Both projects have progressed well and in each case the Company
has been able to successfully load and well disperse Nuvec(R) with
the proprietary products at different doses. This will allow the
testing of a wide range of options with the MTA partners and each
company is now undertaking its own tests with Nuvec(R) and their
respective products. Timing of such work will be dependent on each
party but the Company remains in regular contact whilst the work
continues.
In vivo studies
As announced on 20 May 2021, the Company received good results
from the in vivo pilot dosage study undertaken by Nanomerics using
an OVA plasmid. As a consequence of this study, and the work being
undertaken under the MTA in respect of a plasmid DNA for Covid-19,
the Company took the opportunity to review the scope of the in vivo
work planned at Evotec and to assess other Covid-19 plasmid DNAs
for use with Nuvec(R). The Company has now successfully completed
the amplification and initial testing of a new Covid-19 plasmid at
Evotec and finalised the scope of the in vivo study. This proof of
concept study is now scheduled to start around the middle of
September and is expected to last approximately three months.
Dosage follow-on study
Nanomerics' wider in vivo study will seek to validate the
results seen from the pilot dosage study which, if consistent,
would demonstrate a significant improvement through the use of this
newly formulated Nuvec(R). This follows 18 months of optimisation
and formulation work which has been finalised. Analysis is ongoing
and expected to be completed next month.
In addition to the work above, Nanomerics has been working with
Nuvec(R) in respect of the delivery of TNFalpha in the treatment of
cancer. The initial pilot study to assess the tolerance of
different doses has been concluded successfully and the second
pilot study looking at tumour models will commence shortly and
conclude around the end of next month. After this, the main study
will begin and take a further ten weeks including analysis at which
time the Company will provide an update.
Other studies
At Medicines Discovery Catapult the Company is undertaking
studies to analyse how Nuvec(R) behaves with mRNA both in vitro
(binding, dispersion, stability) and in vivo after subcutaneous
injection.
Finally, in conjunction with the University of Queensland,
following the receipt of a grant from the Australian Government,
the Company is to commence a more substantive study into the oral
application of Nuvec(R). This will be a three-year programme and is
fully funded under the grant.
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"It has been a busy and productive period for the Company across
our different work streams. All studies have progressed well to the
point where we now have visible timelines for their conclusion
throughout the fourth quarter of this year and I look forward to
providing further updates as and when we are able."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
IFC Advisory Ltd Tel: +44(0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDPJMMTMTITTPB
(END) Dow Jones Newswires
August 24, 2021 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Mar 2024 to Apr 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2023 to Apr 2024
